Category Archives: Health Care

Health Care

Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight

In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits

Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile

Continue reading Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease →
Health Care

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer

Dubai, United Arab Emirates; 12 August 2025 — Colon cancer is the third most common cancer in the world. While screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results of the multi-center study were presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Continue reading Immunotherapy boosts chemotherapy in combating stage 3 colon cancer →
Health Care

Lilly’s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05

Progression-free survival data was immature, but trending in favor of pirtobrutinib

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients

Abu Dhabi, United Arab Emirates. August12, 2025:Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations. ORR favored pirtobrutinib with a nominal P-value for superiority1 (p <0.05). Progression free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending in favor of pirtobrutinib. A formal PFS analysis testing for superiority is planned ata future analysis. No detriment was observed for overall survival (OS).

BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients. This important subpopulation (n=225) had the longest follow-up and a particularly pronounced PFS effect size in favor of pirtobrutinib.

The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025.

Continue reading Lilly’s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL →
Health Care

The Royal Marsden Cancer Charity hails Sheikha Jawaher Al Qasimi’s role in advancing precision medicine for cancer treatment

The Sharjah Clinical Genomics Laboratory in the UK is advancing research and bringing hope to thousands of cancer patients

  • A humanitarian initiative by HH Sheikha Jawaher Al Qasimi, the lab was established with a £500,000 donation
  • One of only two UK labs selected by NHS England to evaluate long-read whole genome sequencing for clinical application.
  • Enhancing lung cancer genetic mutation analysis using ‘Liquid Biopsy’ technology
  • Capacity has been doubled to deliver an additional ,000 genetic tests monthly
  • Actively participating in clinical trials for DNA-based personalised therapies
  • The Royal Marsden is a specialist cancer centre that brings together world class researchers and dedicated clinical teams providing expert compassionate care

Sharjah, August 11, 2025,

The Royal Marsden Cancer Charity; which supports the work of The Royal Marsden; has commended the significant support of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah and Founder/Royal Patron of the Friends of Cancer Patients (FoCP). Its annual report highlighted her contributions to advancing cancer research, particularly through initiatives over the past five years that have accelerated progress at the Sharjah Clinical Genomics Laboratory within the National Institute for Health and Care Research (NIHR) Centre for Molecular Pathology (CMP);  housed within The Royal Marsden in the UK. These efforts have greatly enhanced faster delivery of precise diagnoses and cutting-edge personalised treatments for patients.

The report underscored that Her Highness’s support has empowered the lab’s scientific team to fast-track diagnostics and treatments, bringing hope to thousands of patients. This was achieved through the introduction of state-of-the art facilities to the Sharjah Clinical Genomics Laboratory; including the UK’s first robotic genome testing facility; and bringing together world experts in molecular pathology, bioinformatics, translational research.

Continue reading The Royal Marsden Cancer Charity hails Sheikha Jawaher Al Qasimi’s role in advancing precision medicine for cancer treatment →
Health Care

Eyestem Raises Funds to Advance Eyecyte-RPE™ Through Phase 2 Clinical Trial and Towards US IND

India, 11th August 2025: Eyestem Research Pvt Ltd has raised funds in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE™.

The capital will enable completion of the ongoing Phase 2 clinical trial in India and support preparations for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA).

“Strong participation by internal investors and addition of a strategic investor, underline the shared belief in Eyestem’s long-term vision of creating an innovative cell therapy platform providing scalable solutions for incurable diseases worldwide. This  $10 million fundraise will support the next leg of development and strengthen the foundation for global expansion. We continue to prioritize rigorous clinical progress and the capabilities needed to ensure global patient access to this therapy,” said Dr. Jogin Desai, Founder and CEO, Eyestem.

(L to R) Dr Jogin Desai, Dr Rajani Battu & Dr Rajarshi Pal

Continue reading Eyestem Raises Funds to Advance Eyecyte-RPE™ Through Phase 2 Clinical Trial and Towards US IND →